Levonorgestrel News and Research

RSS

Two intrauterine contraceptive systems safe and effective in preventing pregnancies

In a finding that could expand the use of one of the most effective forms of birth control, two intrauterine contraceptive systems that had lower doses of the contraceptive hormone, levonorgestrel, were found to be safe and effective in preventing pregnancies, according to an international study that included researchers at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed).

5 Dec 2013

Researchers create intravaginal ring using MPT to protect women from HIV and unintended pregnancy

A new intravaginal ring (IVR) has been developed for the sustained 90-day co-delivery of tenofovir and levonorgestrel, an anti-human immunodeficiency virus (HIV) drug and a contraceptive.

13 Nov 2013

IPM receives US$40M from USAID to advance new HIV prevention tools for women

The International Partnership for Microbicides (IPM) announced today that it has received two competitive five-year awards with a combined US$40 million ceiling from the US Agency for International Development (USAID).

23 Oct 2013

Quartette tablets now available in U.S. for prevention of pregnancy

Teva Women's Health, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd., today announced that the recently approved Quartette (levonorgestrel/ethinyl estradiol and ethinyl estradiol) tablets are now available via prescription in the U.S. for the prevention of pregnancy.

24 Sep 2013

FDA approves use of Plan B One-Step pill for all women with child-bearing potential

Today, the U.S. Food and Drug Administration announced it has approved the use of Plan B One-Step (levonorgestrel) as a nonprescription product for all women of child-bearing potential.

21 Jun 2013

Questions emerge as dust settles surrounding Plan B policy change

News outlets offer day-after coverage of the Obama administration's reversal on the morning-after contraceptive pill.

13 Jun 2013

Democrats' efforts to revamp Senate filibuster rules tempered by fears on abortion votes

Some supporters of abortion rights fear that any current changes could be used sometime in the future to restrict the option for women. Meanwhile, an appeal court rules that some morning-after pills should be available over the counter immediately.

7 Jun 2013

Federal judge criticizes FDA regarding Plan B contraception decision

Judge Edward R. Korman said the Food and Drug Administration's efforts to delay his ruling regarding the so-called morning-after pill was "nonsense" and would hurt poor and minority women.

9 May 2013

First Edition: May 2, 2013

Today's headlines include reports about a new study detailing how expanded Medicaid access impacts beneficiaries' utilization of health care services and their overall physical health.

2 May 2013

FDA OKs over-the-counter 'Plan B' contraception for women and girls older than age 15

The move, regulators said, was made independent of a recent federal district judge's ruling that called for the emergency contraceptive to be made available over-the-counter to women of all ages without restriction.

2 May 2013

Women & Infants Hospital physician to study treatment options for heavy menstrual bleeding

Kristen A. Matteson, MD, MPH, of the Department of Obstetrics and Gynecology at Women & Infants Hospital and assistant professor of obstetrics and gynecology at The Warren Alpert Medical School of Brown University, has earned a $1.6 million grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health to study the effectiveness of two treatments options for heavy menstrual bleeding.

23 Apr 2013

FDA approves Teva's Quartette tablets for prevention of pregnancy

Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has approved Quartette (levonorgestrel/ethinyl estradiol and ethinyl estradiol) tablets for the prevention of pregnancy.

30 Mar 2013

Mirena coil intrauterine device a better treatment for heavy menstrual periods

The hormone-releasing Mirena coil intrauterine device (IUD) is a better treatment for heavy menstrual periods than other conventional medical approaches, according to results of a major clinical trial led by scientists from the Universities of Nottingham and Birmingham.

11 Jan 2013

IUD insertion does not increase risk of pelvic inflammatory disease in women

The risk of developing pelvic inflammatory disease (PID) following insertion of an intrauterine device (IUD) is very low, whether or not women have been screened beforehand for gonorrhea and chlamydia, according to a joint study of nearly 60,000 women by researchers at the University of California, San Francisco (UCSF), and Kaiser Permanente Northern California Division of Research.

21 Nov 2012

Drospirenone-containing birth control pills associated with increased risk of blood clots

A U.S. Food and Drug Administration-funded study led by the Kaiser Permanente Northern California Division of Research found an increased risk of arterial thrombotic events (ATE) and venous thromboembolic events (VTE) - commonly referred to as blockage of arteries and blood clots, respectively - associated with drospirenone-containing birth control pills compared to four low-dose estrogen combined hormonal contraceptives.

20 Oct 2012

Transvaginal ultrasound effective in treating early-stage endometrial cancer

A common birth control device is effective in treating early-stage endometrial cancer in morbidly obese and high-risk surgery patients, said Georgia Health Sciences University Cancer Center researchers, and could lead to a cost-effective treatment for all women with this cancer type.

17 Oct 2012

Contraceptive patch suppresses ovulation in obese, nonobese women

Use of a novel transdermal contraceptive patch suppresses ovulation in obese and nonobese women, research shows.

12 Oct 2012

FDA accepts Teva's NDA for Quartette oral contraceptive

Teva Women's Health, Inc., a U.S.-based subsidiary of Teva Pharmaceutical Industries Ltd., today announced that the U.S. Food and Drug Administration has accepted for filing its New Drug Application for Quartette (levonorgestrel/ethinyl estradiol tablets and ethinyl estradiol tablets).

13 Aug 2012

FDA approves Watson's ANDA for Next Choice ONE DOSE emergency contraceptive

Watson Pharmaceuticals, Inc. today announced that its subsidiary Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Next Choice ONE DOSE (Levonorgestrel Tablet, 1.5 mg), the generic equivalent to Teva Women's Health's Plan B One-Step. Watson plans to launch the product immediately.

13 Jul 2012

Teva announces new data from women's health franchise

Teva Women's Health today announced new data from the Company's expanding women's health franchise will be featured at the 60th Annual Clinical Meeting of the American Congress of Obstetricians and Gynecologists (ACOG) in San Diego, California, May 5-9, 2012.

5 May 2012